Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
Émilie Le Rhun(University of Zurich), Michael Weller(University Hospital of Zurich), Nicolas Reyns(Centre National de la Recherche Scientifique), Nicolaus Andratschke(University Hospital of Zurich), M. Fialek(Université de Lille), Laurent Mortier, Fabian Wolpert(University of Zurich), Reinhard Dummer(University Hospital of Zurich), Patrick Devos(Hôpital Jeanne de Flandre)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k